ReviewLancet regional health. Americas2025
Call to action: integrating steatotic liver disease into public health strategies in Canada.
Review in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced wait times for hepatology referrals in a prospective quality improvement initiative.Hepatology communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steatotic liver disease (SLD), formerly known as fatty liver disease, is the most common chronic liver condition, affecting one in three people in the Americas, including Canada. Characterized by excess fat in the liver, SLD can progress from a benign state to advanced fibrosis and cirrhosis and is strongly linked to increased risks of cardiovascular disease, extra-hepatic cancers, and premature mortality. Despite its rising prevalence, SLD remains largely absent from Canada's public health agenda. With Canada's aging population, growing rates of obesity and type 2 diabetes, and ethnocultural diversity, the need for a coordinated public health response is urgent. We outline Canada's distinct SLD epidemiology and highlight critical gaps in surveillance, policy, clinical guidelines, screening, and public awareness. We also propose actionable strategies grounded in implementation science to guide the scale-up of effective interventions, thereby strengthening Canada's preparedness and mitigating long-term impacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.